GB00BMVP7Y09
© Globe Newswire
16.12.2025
RPRX
LISTED
NASDAQ
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
News Preview
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent’s neladalkib and zidesamtinib from an undisclosed third party for up to $315 million....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
RPRX
LISTED
NASDAQ
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
News Preview
NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa....
Themefolio
Profiler
Peergroup
© Globe Newswire
26.11.2025
RPRX
LISTED
NASDAQ
Royalty Pharma to Present at Upcoming Investor Conferences
News Preview
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December:...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
05.11.2025
RPRX
LISTED
NASDAQ
Royalty Pharma Reports Third Quarter 2025 Results
News Preview
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
17.10.2025
RPRX
LISTED
NASDAQ
Royalty Pharma Declares Fourth Quarter 2025 Dividend
News Preview
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2025 of $0.22 per Class A ordinary share....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.10.2025
RPRX
LISTED
NASDAQ
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
News Preview
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day....
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
RPRX
LISTED
NASDAQ
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
News Preview
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Bernstein’s 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
11.09.2025
RPRX
LISTED
NASDAQ
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation
News Preview
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) will host an Investor Day in New York City today. Senior executives will provide an update on the company’s plans to drive shareholder value creation through its unique business model and capabilities in the large and growing market for funding biopharma innovation wit...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.09.2025
RPRX
LISTED
NASDAQ
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market
News Preview
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the release of a biopharma royalty market study conducted by Deloitte. The report, titled "Role of Royalties in Funding Biopharma Innovation," is the first of its kind and offers a comprehensive analysis of the current dynamics, growth drivers and outlo...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2025
RPRX
LISTED
NASDAQ
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
News Preview
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:20 p.m. ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.09.2025
RPRX
LISTED
NASDAQ
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
News Preview
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”):...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
RPRX
LISTED
NASDAQ
Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million
News Preview
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Amgen’s Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from BeOne Medicines for $885 million upfront. The agreement includes an option for BeOne to sell additional Imdelltra royalti...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
13.08.2025
RPRX
LISTED
NASDAQ
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors
News Preview
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 and was unanimously appointed as Lead Independent Direct...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.07.2025
RPRX
LISTED
NASDAQ
Royalty Pharma Declares Third Quarter 2025 Dividend
News Preview
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.07.2025
RPRX
LISTED
NASDAQ
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
News Preview
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective immediately. Carole Ho is Chief Medical Officer and Head of Development at Denali Therapeutics, a biopharmaceutical company focused on neurodegenerative dis...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.07.2025
RPRX
LISTED
NASDAQ
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025
News Preview
NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2025 financial results on Wednesday, August 6, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.06.2025
RPRX
LISTED
NASDAQ
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
News Preview
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a $2 billion funding arrangement with Revolution Medicines, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior secured loan of up to $750 million. These funds will support Revolution Medicines’ plans for global developm...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2025
RPRX
LISTED
NASDAQ
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
News Preview
NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
16.05.2025
RPRX
LISTED
NASDAQ
Royalty Pharma Completes the Acquisition of Its External Manager
News Preview
NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC (“RP Management”). The acquisition received overwhelming support from Royalty Pharma’s shareholders, with 99.9% of votes cast in favor of the transaction....
Themefolio
Profiler
Peergroup
© Globe Newswire
13.05.2025
RPRX
LISTED
NASDAQ
Royalty Pharma to Present at Upcoming Investor Conferences
News Preview
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.05.2025
RPRX
LISTED
NASDAQ
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition
News Preview
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition, with 99.9% voting in favor at Royalty Pharma’s 2025 Annual General Meeting and Special Meeting of Shareholders (the “Meeting”), marking a key milestone for th...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.05.2025
RPRX
LISTED
NASDAQ
Royalty Pharma Reports First Quarter 2025 Results
News Preview
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts....
Themefolio
Profiler
Peergroup
© Globe Newswire
21.04.2025
RPRX
LISTED
NASDAQ
Royalty Pharma Declares Second Quarter 2025 Dividend
News Preview
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.04.2025
RPRX
LISTED
NASDAQ
Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025
News Preview
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.04.2025
RPRX
LISTED
NASDAQ
Royalty Pharma Appoints Vlad Coric, M.D. to the Company’s Board of Directors
News Preview
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization o...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.03.2025
RPRX
LISTED
NASDAQ
Royalty Pharma Announces Upcoming Investor Day
News Preview
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m. ET. Royalty Pharma senior executives will provide an update on the company’s plans to drive shareholder value creation through leveraging its uniqu...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.02.2025
RPRX
LISTED
NASDAQ
Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference
News Preview
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on March 4, 2025 at 2:30 p.m. ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
11.02.2025
RPRX
LISTED
NASDAQ
Royalty Pharma Reports Q4 and Full Year 2024 Results
News Preview
NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2024 and introduced full year 2025 guidance for Portfolio Receipts....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2025
RPRX
LISTED
NASDAQ
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
News Preview
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 11, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.01.2025
RPRX
LISTED
NASDAQ
Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
News Preview
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced two major steps to enhance shareholder value....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.01.2025
RPRX
LISTED
NASDAQ
Royalty Pharma Announces Dividend Increase
News Preview
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, reflecting a 5% increase in the company’s quarterly dividend over the previous quarter’s dividend....
Themefolio
Profiler
Peergroup
© Globe Newswire
27.11.2024
RPRX
LISTED
NASDAQ
Royalty Pharma to Present at Upcoming Investor Conferences
News Preview
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December:...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2024
RPRX
LISTED
NASDAQ
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
News Preview
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will acquire a synthetic royalty on U.S. sales of Geron Corporation’s (Nasdaq: GERN) RYTELO for $125 million in cash upfront....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2024
RPRX
LISTED
NASDAQ
Royalty Pharma Reports Third Quarter 2024 Results
News Preview
NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2024 and raised full year 2024 guidance for Portfolio Receipts....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2024
RPRX
LISTED
NASDAQ
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
News Preview
NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that Royalty Pharma has entered into a $350 million synthetic royalty funding agreement with Syndax based on U.S. net sales of Niktimvo (axatilimab-csfr)....
Themefolio
Profiler
Peergroup
© Globe Newswire
16.10.2024
RPRX
LISTED
NASDAQ
Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
News Preview
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day....
Themefolio
Profiler
Peergroup
© Globe Newswire
11.10.2024
RPRX
LISTED
NASDAQ
Royalty Pharma Declares Fourth Quarter 2024 Dividend
News Preview
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ordinary share....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.09.2024
RPRX
LISTED
NASDAQ
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
News Preview
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate p...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.08.2024
RPRX
LISTED
NASDAQ
Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
News Preview
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Morgan Stanley’s 22nd Annual Health Care Conference on September 5, 2024 at 9:15 a.m. ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
19.07.2024
RPRX
LISTED
NASDAQ
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
News Preview
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.07.2024
RPRX
LISTED
NASDAQ
Royalty Pharma Declares Third Quarter 2024 Dividend
News Preview
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A ordinary share....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2024
RPRX
LISTED
NASDAQ
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
News Preview
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024 at 2:00 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/inv...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2024
RPRX
LISTED
NASDAQ
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
News Preview
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”):...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.05.2024
RPRX
LISTED
NASDAQ
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
News Preview
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an interest in Agios Pharmaceuticals’ royalty on Servier’s vorasidenib for $905 million in upfront cash contingent on U.S. Food and Drug Administration (FDA) approval of vorasidenib....
Themefolio
Profiler
Peergroup
© Globe Newswire
22.05.2024
RPRX
LISTED
NASDAQ
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
News Preview
NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company’s expanding cardiovascular pipel...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.05.2024
RPRX
LISTED
NASDAQ
Royalty Pharma to Present at Upcoming Investor Conferences
News Preview
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.05.2024
RPRX
LISTED
NASDAQ
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
News Preview
NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it will acquire royalties and milestones on frexalimab owned by ImmuNext, Inc. (ImmuNext) for approximately $525 million in cash including estimated transaction costs. ImmuNext, a privately-held biotechnology company, is entitled to a royalty on net...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
